Skip to main content
SpringerLink
Log in

The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Asymmetric dimethylarginine (ADMA) is accepted as a risk factor for coronary artery disease because it causes endothelial dysfunction and vasospasm. In this study we aimed to investigate the relationship between ADMA levels and echocardiographic and metabolic parameters in peritoneal dialysis (PD) patients.

Methods

This is a cross-sectional study in which PD patients aged 18–80, with at least 3-month duration of dialysis and without active cardiac, infectious or malignant diseases, and clinically evident hypervolemia, were included. ADMA levels and echocardiographic parameters were recorded.

Results

Of the 55 patients included, the mean age was 53 ± 15 years. Mean ADMA level was 81.9 ± 48.0 μmol/l. The variables found to be positively correlated with ADMA levels were weight, body surface area, body mass index (BMI), serum glucose level, uric acid and sodium levels, ultrafiltration volume, left atrium diameter, intraventricular end-systolic diameter and intraventricular end-diastolic diameter. The parathyroid hormone, dialysate K t/V and ejection fraction were negatively correlated with ADMA levels. ADMA levels were higher in patients with hypertension. With multivariate analysis, gender, BMI and use of acetyl salicylic acid were found to be the independent variables determining ADMA levels.

Conclusion

The correlation of ADMA with BMI, gender, hypertension, left atrium diameter, intraventricular end-systolic diameter and intraventricular end-diastolic diameter led to the idea that ADMA may aid in the determination of cardiovascular disease risk in PD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miller LM, Sood MM, Sood AR, Reslerova M, Komenda P, Rigatto C, et al. Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol. 2010;42:1007–14.

    Article  PubMed  CAS  Google Scholar 

  2. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from l-arginine: a pathway for the regulation of cell function and communication. Biochem Pharmacol. 1989;38:1709–15.

    Article  PubMed  CAS  Google Scholar 

  3. Yılmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol. 2008;19(2):388–95.

    Article  PubMed  Google Scholar 

  4. Fliser D, Kielstein JT, Haller H, Böger SMB. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int. 2003;63(84):37–40.

    Article  Google Scholar 

  5. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol. 1995;269:1522–7.

    Google Scholar 

  6. Çakir E, Özcan O, Yaman H, Akgul EO, Bilgi C, Erbil MK, et al. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. J Clin Endocrinol Metab. 2004;90(3):1651–4.

    Article  PubMed  Google Scholar 

  7. Avcı E, Coskun S, Çakır E, Kurt Y, Ozgur Akgul E, Bilgi C. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients. Ren Fail. 2008;30(8):784–90.

    Article  PubMed  Google Scholar 

  8. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613–8.

    Article  PubMed  CAS  Google Scholar 

  9. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505–21.

    Article  PubMed  CAS  Google Scholar 

  10. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:1–153.

    Google Scholar 

  11. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092–5.

    Article  PubMed  CAS  Google Scholar 

  12. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tanqphao O, et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98:1842–7.

    Article  PubMed  Google Scholar 

  13. Fleck C, Schweitzer F, Karge E, Busch M, Stein G. Serum concentration of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003;336:1–12.

    Article  PubMed  CAS  Google Scholar 

  14. Kielstein JT, Böger RH, Bode-Böger SM, Schaffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594–600.

    PubMed  CAS  Google Scholar 

  15. Ebinç FA, Erten Y, Ebinç H, Paşaoğlu H, Demirtaş C, Taçoy G, et al. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients. Ren Fail. 2008;30(4):401–6.

    Article  PubMed  Google Scholar 

  16. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46(3):518–23.

    Article  PubMed  CAS  Google Scholar 

  17. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl. 2003;4:61–5.

    Article  PubMed  CAS  Google Scholar 

  18. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15:77–80.

    Article  Google Scholar 

  19. Hodis HN, Mack WJ, Labree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262–9.

    Article  PubMed  CAS  Google Scholar 

  20. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 2005;67:2330–7.

    Article  PubMed  CAS  Google Scholar 

  21. Lin KY, Ito A, Asagami T, Adimoolam S, Kimoto M, Tsuji H, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987–92.

    Article  PubMed  CAS  Google Scholar 

  22. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia. 2002;45(12):1609–16.

    Article  PubMed  CAS  Google Scholar 

  23. Kryzuzanowska K, Mittermayer F, Kopp HP, Wolzt M, Scherthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab. 2004;89:277–81.

    Google Scholar 

  24. Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Plasma adhesion and inflammation markers: asymmetrical dimethyl-l-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg. 2007;17:672–8.

    Article  PubMed  Google Scholar 

  25. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking and the endogen nitric oxide synthase inhibitor, ADMA. Metabolism. 2004;53:1574–9.

    Article  PubMed  CAS  Google Scholar 

  26. McLaughlin T, Stühlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab. 2006;91:1896–900.

    Article  PubMed  CAS  Google Scholar 

  27. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adeqoke OA, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2005;21:1–9.

    Google Scholar 

  28. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tanqphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842–7.

    Article  PubMed  Google Scholar 

  29. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimaki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol. 2001;38(4):561–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors have declared that no conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Nephrology, Haseki Training and Research Hospital, Istanbul, Turkey

    Savas Ozturk, Serhat Karadag, Meltem Gursu, Sami Uzun & Zeki Aydin

  2. Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey

    Metin Yegen & Baki Kumbasar

  3. Department of Cardiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Ahmet Gurdal

  4. Department of Biochemistry, Haseki Training and Research Hospital, Istanbul, Turkey

    Macit Koldas

  5. Department of Nephrology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey

    Rumeyza Kazancioglu

  6. Nefroloji Klinigi, Haseki Egitim ve Arastirma Hastanesi, Fatih, Istanbul, Turkey

    Meltem Gursu

Authors
  1. Savas Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serhat Karadag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Metin Yegen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meltem Gursu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sami Uzun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zeki Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmet Gurdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Macit Koldas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Baki Kumbasar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rumeyza Kazancioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meltem Gursu.

About this article

Cite this article

Ozturk, S., Karadag, S., Yegen, M. et al. The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients. Clin Exp Nephrol 17, 431–436 (2013). https://doi.org/10.1007/s10157-012-0739-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0739-7

Keywords

Search

Navigation